Source comparison
Pe-22-28 vs Semax Amidate: Research Comparison
The following comparison synthesizes pharmacokinetic data, receptor activity profiles, and practical research application differences to guide protocol selection. Half-Life 8–10 hours (subcutaneous) 2–3 hours (intranasal) Pe-22-28 allows once or twice-daily do
This comparison does not assign a generated winner or score.
- The following comparison synthesizes pharmacokinetic data, receptor activity profiles, and practical research application differences to guide protocol selection.
- Half-Life
- 8–10 hours (subcutaneous)
- 2–3 hours (intranasal)
- Pe-22-28 allows once or twice-daily dosing; Semax requires 3–4 daily administrations for sustained effect
- Primary Route
- Subcutaneous injection
- Intranasal delivery
- Semax offers non-invasive administration reducing handling stress; Pe-22-28 provides more predictable systemic bioavailability
- MC4R Binding Affinity
- 15–20 nM (Ki)
- 40–50 nM (Ki)
- Pe-22-28 produces stronger melanocortin receptor engagement at equivalent doses
- BDNF Elevation Onset
- 2–4 hours
- 60–90 minutes
- Semax triggers faster neuroplastic signaling initiation
- BDNF Elevation Duration
- 24–30 hours
- 10–12 hours
- Pe-22-28 sustains neuroplastic signaling across full circadian cycle
- NMDA Receptor Activity
- Minimal direct modulation
- Glycine-site potentiation
- Semax provides acute glutamatergic enhancement Pe-22-28 lacks
- Optimal Study Duration
- 4–12 weeks chronic
- Acute to 2-week interventions
- Match peptide half-life to endpoint measurement timeline
- Washout Period
- 48–72 hours to baseline
- 12–16 hours to baseline
- Semax enables faster crossover designs and dose-escalation studies
- Professional Assessment
- Pe-22-28 is the superior choice for chronic neuroplasticity protocols requiring sustained BDNF elevation and once-daily dosing convenience
- Semax Amidate excels in acute cognitive intervention studies where rapid onset, NMDA potentiation, and non-invasive delivery are prioritized
- Select based on study duration and whether cumulative adaptation or acute performance modulation is the primary endpoint